Citigroup Inc Merus N.V. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Merus N.V. stock. As of the latest transaction made, Citigroup Inc holds 1,211 shares of MRUS stock, worth $60,138. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,211

Previous 1,519 20.28%

Holding current value

$60,138

Previous $89,000 32.58%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$47.19 - $58.84 $14,534 - $18,122	-308 Reduced 20.28%	1,211 $60,000
Q2 2024 Aug 12, 2024	BUY	$39.81 - $60.2 $51,195 - $77,417	1,286 Added 551.93%	1,519 $89,000
Q1 2024 May 10, 2024	SELL	$28.03 - $51.82 $23,292 - $43,062	-831 Reduced 78.1%	233 $10,000
Q4 2023 Feb 09, 2024	BUY	$20.06 - $28.66 $5,255 - $7,508	262 Added 32.67%	1,064 $29,000
Q3 2023 Nov 09, 2023	SELL	$20.13 - $27.29 $39,817 - $53,979	-1,978 Reduced 71.15%	802 $18,000
Q2 2023 Aug 10, 2023	SELL	$18.33 - $27.18 $12,647 - $18,754	-690 Reduced 19.88%	2,780 $73,000
Q1 2023 May 11, 2023	SELL	$14.25 - $20.5 $855 - $1,230	-60 Reduced 1.7%	3,470 $63,000
Q4 2022 Feb 09, 2023	BUY	$12.8 - $23.66 $10,278 - $18,998	803 Added 29.45%	3,530 $54,000
Q3 2022 Nov 10, 2022	SELL	$18.64 - $28.93 $2,945 - $4,570	-158 Reduced 5.48%	2,727 $55,000
Q2 2022 Aug 10, 2022	SELL	$13.98 - $29.25 $1.65 Million - $3.46 Million	-118,272 Reduced 97.62%	2,885 $65,000
Q1 2022 May 12, 2022	BUY	$23.58 - $30.91 $930,914 - $1.22 Million	39,479 Added 48.33%	121,157 $3.2 Million
Q4 2021 Feb 10, 2022	SELL	$20.0 - $32.29 $712,380 - $1.15 Million	-35,619 Reduced 30.37%	81,678 $2.6 Million
Q3 2021 Nov 10, 2021	BUY	$16.48 - $27.23 $1.93 Million - $3.19 Million	117,297 New	117,297 $2.58 Million

Others Institutions Holding MRUS

# of Institutions

200

Shares Held

61.9M

Call Options Held

243K

Put Options Held

300K

View Full List

About Merus N.V.

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

More about MRUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account